Expression of c-erb B-2 oncoprotein in cancer of the larynx in relation to invasion of the cartilagenous framework and prognosis

Tantawy, A. O.; Youins, L.; Hamza, M.

doi:10.1007/s004050050119

Cited by 12 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While over-expression of p53 was significantly associated with the presence of lymph node metastases (P = 0.006), we failed to find any significant correlation between c-erbB-2 and lymph node status. This result is consistent with previous studies showing no correlation between lymph node status and c-erbB-2 positive immunostaining [7,19]. Our result is similar to the studies that reported higher p53 expression when lymph node metastases were present [2,15].…”

Section: Discussionsupporting

confidence: 96%

“…The same findings were reported by other authors [2,7,13,19,21]. While over-expression of p53 was significantly associated with the presence of lymph node metastases (P = 0.006), we failed to find any significant correlation between c-erbB-2 and lymph node status.…”

Section: Discussionsupporting

confidence: 82%

“…It encodes a transmembrane glycoprotein with thyrosine kinase activity and shares extensive structural similarity with the epidermal growth factor receptor. The oncogene potential of c-erbB-2 can be released by point mutations, truncation of extracellular and cytoplasmic domains, and amplification and/or over-expression of the normal gene [5,7,10,19,21]. Over-expression of the c-erbB-2 protein has been found in several human cancers (SCCs of the head and neck, primary carcinoma of the breast, ovary, pancreas, various adenocarcinomas, and salivary gland cancers).…”

Section: Introductionmentioning

confidence: 98%

“…Mutations of the genes affect the normal cell cycle or increase the expression of the gene product. Due to these alterations, tumorigenesis occurs [19].…”

Section: Introductionmentioning

confidence: 99%

“…While over-expression of c-erbB-2 correlates with a poor prognosis in those cancers, it has no prognostic value in bladder and biliary tract carcinomas [7,10]. In recent years, c-erbB-2 over-expression in LSCC has been reported in from 34% to 55% of tumors [5,7,19,21].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Over-expression of p53 and c- erbB-2 oncoproteins in laryngeal carcinoma

Kazkayası¹,

Hücümenoğlu

Siriner³

et al. 2001

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

An immunohistochemical analysis of over-expression of p53 and c-erbB-2 proteins was performed on 27 biopsies of laryngeal carcinoma. The aim of this study was to investigate whether there is a correlation between over-expression of these proteins and the clinicopathological features of the tumor and to reveal any possible prognostic value. Paraffin sections of laryngeal carcinoma were studied using immunohistochemical staining with mouse and rabbit monoclonal antibodies, respectively, for p53 and c-erbB-2 proteins. The positive controls were paraffin-embedded specimens from ten breast carcinomas previously shown to express these proteins. Ten benign laryngeal nodules were immunohistochemically stained as negative controls. Samples from 74% of 27 patients with laryngeal carcinomas demonstrated positive nuclear and cytoplasmic (or membranous) staining for p53 protein and 48% were positive for c-erbB-2 protein. In the present study, while there was a slight difference in the frequency of p53 over-expression among stage I-II and stage III-IV tumors, there was no difference in the frequency of p53 over-expression among primary and recurrent tumors. There was no statistically significant correlation between over-expression of the p53 and c-erbB-2 proteins and the age of the patients, tumor site, tumor grade, clinical stage, histopathological grading of the tumor, alcohol consumption, and clinical outcome. There was a statistically significant correlation between immunostaining of p53 and c-erbB-2 proteins (P = 0.037). While it was found that over-expression of p53 was significantly associated with the presence of lymph node metastasis (P = 0.006), there was no association between the expression of c-erbB-2 and lymph node status. The data demonstrated increased expression of p53 and c-erbB-2 proteins, presumed to be mutant, in laryngeal carcinomas. Hence, we conclude that p53 and c-erbB-2 over-expression as detected by immunohistochemical staining in larynx carcinomas is not predictive of poor survival or disease-free survival.

show abstract

Section: Discussionsupporting

confidence: 96%

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 98%

“…Mutations of the genes affect the normal cell cycle or increase the expression of the gene product. Due to these alterations, tumorigenesis occurs [19].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Over-expression of p53 and c- erbB-2 oncoproteins in laryngeal carcinoma

Kazkayası¹,

Hücümenoğlu

Siriner³

et al. 2001

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

show abstract

Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: Antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma

et al. 2012

View full text Add to dashboard Cite

The choice of postremission therapy for acute myeloid leukemia (AML) patients is now based on the blasts' cytogenetic and molecular profile. However, the potential benefit of autologous hematopoietic stem cell transplantation (auto‐HSCT) according to the NPM1/FLT3‐ITD status has been poorly studied in AML patients with a normal karyotype (NK). Therefore, we evaluated the NPM1/FLT3‐ITD molecular status in 135 NK‐AML patients treated by allogeneic HSCT (allo‐HSCT), auto‐HSCT, or chemotherapy as consolidation therapy within the GOELAMS LAM‐2001 trial. In univariate analyzes, 4‐year leukemia‐free survival (LFS) and overall survival (OS) were significantly higher for NPM1+/FLT3‐ITD− patients compared with patients presenting another molecular profile (61 vs. 43% and 72 vs. 48%, P = 0.02 and P = 0.01, respectively). In the NPM1+/FLT3‐ITD− subgroup, there was no benefit for allo‐HSCT or auto‐HSCT vs. chemotherapy (4‐year LFS: 71, 56, and 60%; 4‐year OS: 73, 71, and 60%, respectively; P = NS). For patients with other NPM1/FLT3‐ITD molecular profiles, allo‐HSCT was found to be the best consolidation therapy, whereas auto‐HSCT was associated with a better outcome when compared with chemotherapy (allo‐HSCT‐, auto‐HSCT‐, and chemotherapy‐related 4‐year LFS: 68, 44, and 36%, P = 0.004; 4‐year OS: 68, 52, and 29%, respectively, P = 0.02). Our study indicates that allo‐HSCT and auto‐HSCT provide similar outcomes compared with chemotherapy as consolidation for NPM1+/FLT3‐ITD− NK‐AML patients. For NK‐AML patients with an adverse molecular profile, auto‐HSCT could represent an alternative therapeutic approach when no human leukocyte antigen–matched allogeneic donor is available. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.

show abstract

Prognostic value of oncoprotein expressions in thyroid papillary carcinoma

et al. 2011

View full text Add to dashboard Cite

The aim of this study was to evaluate the expressions of oncoproteins and to correlate the results with clinicopathologic parameters in papillary thyroid carcinoma (PTC). Papillary thyroid cancer (PTC) is the most common form and accounts for about 80% of all thyroid cancers. Although PTC generally has a good prognosis, some patients suffer from local recurrence and/or distant metastasis. Oncogenes have reported to be related not only in carcinogenesis but also in tumor prognosis, tumor type, differentiation and site of tumor in epithelial malignant tumors such as thyroid, breast, ovarian, and stomach cancer. This study was planned retrospectively and was performed in 87 patients (47 PTC, 40 benign lesions). The data of clinicopathologic parameters and tissue samples were collected from the archives. Sections stained with H&E were evaluated for each case and after confirming the diagnosis of PTC, oncoprotein expressions were determined by immunohistochemical analysis. The differences of oncoprotein expressions in PTC compared with control group were statistically significant. Cyclin D1 and p53 expressions were significantly increased in PTC. The expressions of bcl-2 and c-erbB-2 in PTC were found as increased, but the correlation between these proteins and poor prognostic parameters were not significant. We suggest that increased expressions of cyclin D1 and p53 could be used as prognostic factors in patients with PTC.

show abstract

Expression of c-erb B-2 oncoprotein in cancer of the larynx in relation to invasion of the cartilagenous framework and prognosis

Cited by 12 publications

References 21 publications

Over-expression of p53 and c- erbB-2 oncoproteins in laryngeal carcinoma

Over-expression of p53 and c- erbB-2 oncoproteins in laryngeal carcinoma

Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: Antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma

Prognostic value of oncoprotein expressions in thyroid papillary carcinoma

Contact Info

Product

Resources

About